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The efficiency of regenerative medicine can be ameliorated by improving the biological performances of stem
cells before their transplantation. Several ex-vivo protocols of non-damaging cell hypoxia have been demonstrated
to significantly increase survival, proliferation and post-engraftment differentiation potential of stem cells. The best
results for priming cultured stem cells against a following, otherwise lethal, ischemic stress have been obtained
with brief intermittent episodes of hypoxia, or anoxia, and reoxygenation in accordance with the extraordinary
protection afforded by the conventional maneuver of ischemic preconditioning in severely ischemic organs. These
protocols of hypoxic preconditioning can be rather easily reproduced in a laboratory; however, more suitable
pharmacological interventions inducing stem cell responses similar to those activated in hypoxia are considered
among the most promising solutions for future applications in cell therapy. Here we want to offer an up-to-date
review of the molecular mechanisms translating hypoxia into beneficial events for regenerative medicine. To this
aim the involvement of epigenetic modifications, microRNAs, and oxidative stress, mainly activated by hypoxia
inducible factors, will be discussed. Stem cell adaptation to their natural hypoxic microenvironments (niche) in
healthy and neoplastic tissues will be also considered.
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Introduction
Stem cells (SCs) are currently evaluated as a tool to
repair the irreversible tissue damages that permanently
impair organ function. In the last decade, the increas-
ing knowledge of SC biology has widely encouraged
preclinical and clinical studies of regenerative medicine.
SCs are unspecialized cells maintaining their prolifera-
tive and differentiative capacity throughout the life of
an individual [1]. Their ability to divide and remain in
the undifferentiated state, i.e. the self-renewal process,
is a specific characteristic of these cells that can be
accomplished by two mechanisms known as obligatory
asymmetric replication and stochastic differentiation
[2]. The former splits SCs into two daughter cells, one
of which retains the property of self-renewal while the
other begins to differentiate; the second requires the
participation of SCs that generate two identical daughter* Correspondence: claudio.muscari@unibo.it
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reproduction in any medium, provided the orcells together with SCs that generate only differentiating
cells.
According to their differentiation potential, or potency,
mammal SCs are classified as [3]: totipotent, namely the
zygote and its first daughter cells which give rise to the
entire organism; pluripotent, i.e. the blastocystic cells
that differentiate into any of the three germ layers;
multipotent, that are present in the fetus and born
organisms and can differentiate into multiple, but
limited cell types; oligopotent, such as the lymphoid or
myeloid SCs, that differentiate into a few cell types;
unipotent, that produce only one cell type but are still
self-renewing. Similarly to unipotent SCs, progenitor
cells are also unipotent but can divide only a limited
number of times.
Furthermore, SCs can be distinguished into two categor-
ies: pluripotent embryonic SCs (ESCs) and multipotent
or unipotent adult (somatic) SCs, the latter being
present in near all post-natal tissues including bone
marrow, blood, adipose tissue, skin, liver, muscle, and
brain [4]. The picture is completed by the so-called
induced pluripotent SCs (iPSCs), that are not naturallyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of cells by forcing the expression of a few genes that
provide pluripotency [5].
An open question concerns the putative property of
adult SCs to differentiate into cell phenotypes inde-
pendent from the expected commitment by the tissue
where they reside [6]. This plasticity of adult SCs might
contribute a certain advantage for in-vivo tissue repair.
For instance, it has been suggested that after an organ
ischemic insult bone-marrow mesenchymal SCs (BM-
MSCs) are mobilized into blood and recruited in the
injured tissue where they could in part participate to
the regeneration process via transdifferentiation [7].
Therefore, the interest on adult SCs, as opposed to
ESCs, has rapidly increased because the former are
easily accessible in the patient, do not rise ethical
concerns, retain a reduced risk of tumor formation, do
not require immunosuppressive treatments to prevent
rejection, and could show some plasticity. However,
although multipotent SCs show many characteristics
that can be suitable for clinical applications, their use
in regenerative medicine is often hampered by their
poor survival after the engraftment [8-10]. Indeed, the
injured tissue is usually fibrotic and poorly perfused;
hence, the insufficient availability of oxygen and nutrients
renders both grafted and resident SCs more susceptible
to lethal damage.
Strategies have been proposed to ameliorate the repair
of post-ischemic tissues, including SC-induced neova-
scolarization [11-13] and SC preconditionings able to
improve SC survival after transplantation [14,15]. Both
approaches are considered hot topics of the research in
the field since they could significantly improve the
clinical outcome of cell therapy.
Among the experimental procedures employed in the
last decades for attenuating the damage induced by
acute and severe ischemic events, in-vivo organ pre-
treatments with brief cycles of ischemia and reperfu-
sion, namely “Ischemic Preconditioning” (IP), has been
widely recognized as the best protective maneuver
[16,17]. Nowadays, these basic experiences have been
successfully translated into clinical interventions to
prevent the potential damage due to the temporary
interruption of blood perfusion during surgery [18-20].
In a similar manner, hypoxia-dependent pretreatments
on SCs have been investigated to increase their survival
for applications in regenerative medicine (Figure 1).
Here, we will consider at first the effects exerted by
hypoxia on SC viability in their natural microenvironment,
to underline what molecular and cellular adaptations
they develop to face this unusual condition. Then, suitable
methods inducing SC protection after exposure to dif-
ferent protocols of low oxygen tension will be discussed,
as well as the need to discover pharmacological treatmentstriggering the same intracellular signaling pathways
leading to hypoxic adaptation. Finally, the role of non-
damaging hypoxic conditions in enhancing SC prolifer-
ation and differentiation will be also described.
Lesson from SCs resident in a natural hypoxic
microenvironment
Basic features of SC niche
The fate of SCs in their natural environment is regulated
by intrinsic and extrinsic signals balancing both cell self-
renewal and differentiation. The extrinsic factors are
included in the term “niche” that was first proposed in
1978 by Schofield, who defined a somehow specific
microenvironment supporting the cells [21]. In their
niche, SCs are supposed to be influenced by different
molecules such as cytokines and growth factors (e.g.
basic fibroblast growth factor (bFGF), bone morpho-
genetic proteins (BMPs), stem cell derived factor 1
(SDF-1), stem cell factor (SCF), leukemia inhibiting
factor (LIF), Wnt/β-catenin [22]), extracellular matrix
(ECM) molecules (e.g. hyaluronan [23]), some differenti-
ated cells (e.g. fibroblasts, endothelial cells), and low O2
concentrations [24]. Niches of mammalian adult SCs
have been described in various tissues and hypoxia
appears to represent a stimulus promoting self-renewal
[25]. For instance, two distinct niches for hematopoietic
stem cells (HSCs) have been identified in bone marrow:
the hypoxic endosteal niche and the vascular niche [26].
While the former is hypothesized to maintain SCs in
a quiescent and undifferentiated state through the
hypoxic environment, the latter should promote both
SC proliferation and differentiation. In this regard,
Notch signaling seems to be critical since its inhibition
reverse the effects of hypoxia on the maintenance of
stemness [27].
In the attempt to explain why hypoxia is needed for
the maintenance of a SC pool, some studies suggested
that mild-low levels of O2 can minimize the damages
caused by oxidation, especially towards DNA [28]. In-
deed, according to the clonogenic theory, no changes
in gene structure must occur in dividing SCs that have
to be the exact copy of their mother cells. However,
this concept is under debate since hypoxia has also
been reported as increasing, rather than blunting, oxi-
dative stress [29].
Role of hypoxia inducible factor-1α in SC adaptation
to hypoxia
One of the most powerful way followed by SCs to adapt
to the low oxygen tension that characterizes the niche
is the production of high levels of hypoxia inducible
factors (HIFs) [30]. HIFs are activated when oxygen
tension falls below 5% and their concentrations increase
in parallel with decreasing oxygenation [31]. HIFs are
αα
α
Figure 1 Efficacy of hypoxic pretreatments of adult SCs in regenerative medicine. Grafted SCs become more resistant to the death stimuli
that are present in the injured tissues through ex-vivo hypoxic pretreatments (continuous hypoxia or cyclic hypoxia-anoxia and reoxygeneation)
or by administration of CoCl2. Pharmacological agents exerting intracellular key effects of hypoxic preconditioning, such as diazoxide, can also be
effective. The most common sensor activated under low oxygen tensions is HIF-1α which increases cell survival by stimulating several pathways,
including glycolytic flow, Akt phosphorylation, and miRs upregulation. Transgenic induction of miR-107 and miR-210, which are mainly expressed
after hypoxia, also provides protection to SCs against the engraftment injury.
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adaptation to hypoxia whose active form results from
the interaction of α and β subunits; the former includes
HIF-1α, HIF-2α, and HIF-3α, the latter HIF-1β and
HIF-2β. Mechanisms of activation and target genes
have been better documented for the HIF-1α subunit
[32]. Under normoxic conditions, the prolyl residues in
the HIF-1α oxygen-dependent degradation domain (ODD)
are hydroxylated by at least three different HIF prolyl
hydroxylases (PHDs) [33]. Besides molecular oxygen,
hydroxylation needs the presence of 2-oxoglutarate and
reduced iron ions. Moreover, a factor inhibiting HIF
(FIH) hydroxylates a specific asparaginyl residue which
prevents the following recruitments of co-activator
p300/CBP in the consensus sequences. The hydroxylated
ODD is then recognized by von Hippel-Lindau protein
(VHL), an E3 ubiquitin ligase. When oxygen tension is
low, PHDs are not hydroxylated, hence they become
inactive and HIF-1α is stabilized because it is not degraded
by the proteasome system [32]. Besides hypoxia, certain
intracellular metabolites, including reactive oxygen species
(ROS), fumarate, succinate, and potentially 2-hydroxy-
glutarate, inhibit PHD and FIH activities, resulting inHIF-1α stabilization [34]. HIF-1α thus heterodimerizes
with HIF-1β, also known as arylhydrocarbon receptor
nuclear factor (ARNT), and translocates into the nucleus
where it binds to hypoxia response elements (HRE)
along with the co-factors E1A binding protein p300
(EP300), jun proto-oncogene (c-JUN), and cAMP respon-
sive element binding protein (CREB) [35]. This leads
the modulation of up to 200 genes involved in several
processes including angiogenesis, glycolysis, mitochondrial
respiration and biogenesis, production of erythropoietin,
redox homeostasis, cell proliferation and cell apoptosis,
in both normal and tumor cells [36]. More recently,
several other modulators of HIFs stability and gene
transcription have been discovered, such as chaperonins,
transcriptional co-factors, sirtuins, ascorbate, nitric oxides,
microRNAs, oncogenes, tumor suppressors, and inflam-
mation factors [34,37].
Epigenetic changes induced by hypoxia
The changes in gene expression upon hypoxic stress
are tightly associated with modifications in chromatin
structure by histone modifying and chromatin remodeling
complexes, that are referred to as epigenetic regulation
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it has been reported that during hypoxia, the SWI/SNF
chromatin remodeling complex [39] is recruited to the
promoter of the HIF-1α gene, where it is required for
expression of HIF-1α mRNA [40] as a conserved feature
in animal evolution [41].
HRE-containing gene promoters are affected by up-
regulated HIF-1α together with its co-activators involved
in the epigenetic regulation of histone marks and DNA
methylation. The former includes the acetylation and/Figure 2 Schematic representation of hypoxia-induced epigenetic cha
mechanisms, included epigenetic modifications. The induced upregulation
Also stem-related genes, such as OCT-4, could be re-expressed. The chroma
transcription factors, also consequently to the upregulation of histone dem
histone marks (H3K9me2/3). Histone tails are characterized by active histon
or H3K4me2/3, and DNA is unmethylated (white rounds) at the promoter C
transcription, associated with the upregulation of chromatin modifier enzym
that drive the formation of histone repressive marks (red and purple round
methylation global level increases consequently to the upregulation of DN
additional control of transcription and translation contributes to generate a
increase protection from oxidative stress, reduce DNA damage, increase gly
viability and their regenerative potential.or methylation of specific residues of H3 and H4 his-
tone tails, the latter the adduction of methyl group on
cytosine preceding guanine (CpG) in the DNA se-
quence of the target gene promoter. Indeed, the inter-
play between these chemical modifications and the
protein complexes influencing chromatin architecture
leads to the typical hypoxic transcriptional confi-
guration, where HIF target genes are upregulated al-
though general transcription in the cell is substantially
inhibited [42].nges. Hypoxic conditions modulate SCs expression profile via several
of HIF-1α and HIF-2α, drives the activation of several target genes.
tin configuration of their promoter region becomes accessible to
ethylases JMJD1A and JMJD2B, that catalyse the removal of repressive
e modifications (light or dark blue squares), such as acetylated H3-H4
pG sites (black lines). Hypoxia also induced global repression of gene
es, such as histone deacetylases (HDACs) and demethylases (G9a),
s), such as deacetylated H3-H4, H3K9me2/3 or H3K27me3. DNA
A methyltransferases (DNMTs) and gene expression is silenced. MiRNAs
gene expression profile that allows to reactivated stem-related genes,
colysis and angiogenesis, with the final result of enhancing cell
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role as enzymes involved in this epigenetic control. The
impact of histone methylation appears context-de-
pendent: tri-methylation of lysine 27 in H3 histone tail
(H3K27me3) indicates transcriptionally repressed chro-
matin. The same holds true for methylated H3K9. On
the other hand, the promoter region of active genes ap-
pears enriched in methylated H3K4 and/or H3K36 [43].
Interestingly, the Jumonji domain containing dioxy-
genases (JMID) group of histone demethylases (JHDMs),
and in particular JMJD1A and JMJD2B, are induced
under hypoxic conditions by the overexpression of HIF-
1α and HIF-2α [44]. This class of histone demethylases
removes methyl-group from histone H3 tails, leading to
the loss of repressive histone marks. In detail, JMJD1A
catalyses the formation of mono-methyl lysine 9 in H3
histone tail (H3K9me1) from di-methyl lysine (H3K9
me2), whereas JMJD2B removes a methyl group from
tri-methyl lysine 9 in H3 histone tail (H3K9me3) produ-
cing H2K9me2. The removal of these repressive histone
marks has been associated with the restoration of the
expression of self-renewal genes, such as OCT-4 in SCs
[44], as supported also by other authors that found
JMJD1A and JMJD2C enhancing the expression of self-
renewal genes in embryonic SCs [45].
In hypoxic condition SCs are prone to assume a phe-
notype more similar to ESCs, with enhanced capacity of
differentiation and proliferation, as supported by several
studies, that show hypoxia promoting de-differentiation
of early committed ESCs reacquiring pluripotency [46],
or hypoxic condition accelerating the process of repro-
gramming of iPSCs [47]. These observations underline
that the epigenetic machinery in adult SCs is devoted
not only to drive their differentiation but also to main-
tain their stemness [48-50], two opposite effects requir-
ing a well-orchestrated control at the level of master
genes driving cell differentiation and division.
Besides local changes in the chromatin structure in
the region of HIF-target genes leading to their activation,
hypoxia has also been found to provoke a dramatic
decrease of gene transcription that seems to be influenced
by epigenetic modifications [38,42]. Among the transcrip-
tional repressive modifications hypoxia is also known
to induce global deacetylation of histones [51], as well
as increased H3K9me level induced by the up-regu-
lation of histone methyltransferase G9a [52]. Increased
level of global DNA methylation following the upre-
gulation of the DNA methyltransferases (DNMTs) has
also been reported in several studies [51].
An additional level of regulation controlled by hypoxia
in SC niches are microRNA (miRs), short non-coding
RNA molecules regulating, in a sequence-specific manner,
gene expression via translational repression or mRNA
degradation [53]. Under hypoxic conditions, miR-210expression is significantly increased, modulating the levels
of iron-sulphur cluster protein (ISCU), a protein which
is involved in the mitochondrial electron transport
chain [51]. Other groups of miRs seem to regulate vas-
cular endothelial growth factor (VEGF) which, in turn,
stimulates angiogenesis [54]. Interestingly, some of these
miRs are downstream effectors of HIFs, providing further
evidence that most changes induced by hypoxia are strictly
under the control of these transcription factors. HIF-1α
is also involved in cell cycle regulation, as shown in
HSCs where heterozygous deletion of von Hippel-Lindau
factor (VHL) causes enhanced HIF-1α expression and
cell quiescence [55]. Moreover, in the hypoxic niche the
proliferating hematopoietic cell fraction re-enters cell
cycle quiescence. The HIF-1α target factors that poten-
tially correlate with these effects of hypoxia in HSCs
are VEGF and Cripto/GRP78 signaling, whose presence
has been shown in the niche of various SCs, including
HSCs an MSCs.
Role of hypoxia in the cancer SC niche
Most of the above-mentioned adaptations of adult SCs
to hypoxia under healthy conditions have also been
found in cancer stem cells (CSCs). These cells, which
share many characteristics with normal SCs, seem to be
necessary for tumor maintenance, progression, and ma-
lignancy [56]. As for adult SCs, most CSCs reside in
hypoxic niches where their functions depend on several
autocrine/paracrine factors, ECM molecules, and non-
tumor cells. Notably, in respect to bulk tumor cells, the
expression of HIF-1α is higher in CSCs leading to in-
crease survival and progression to more aggressive and
undifferentiated phenotypes [57]. Other findings have
shown that oxygen levels are subjected to significant
fluctuations in tumor niches and that these intermittent
episodes of hypoxia and reoxygention are even more
effective in promoting CSC survival and progression
than continuous hypoxia [58].
All these observations clearly demonstrate that both
normal and cancer stem cells develop several mecha-
nisms of adaptation to hypoxia that provide them in-
creased resistance to different stresses. This suggests
useful cues to simulate under ex-vivo conditions a simi-
lar environment to improve the performances of SCs
addressed to cell therapy applications.
Hypoxia-dependent conditions improving ex-vivo
SC survival
Hypoxic preconditioning of SCs
The poor vascularization of the injured tissues, especially
if damaged by an ischemic insult, meets only partially
the metabolic needs of the transplanted cells, hence
more than 80-90% of cells undergo apoptosis within
the first days after grafting [59]. In the attempt to
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been suggested to increase the cell ability to survive to
hypoxia (Table 1).
Since IP seems to be the most potent strategy to pro-
tect organs against severe ischemia, this approach was
adopted in some clinical context, for instance to reduce
the cardiac injury that follows coronary stent or bypass
applications [19,20]. Almost conclusive findings dem-
onstrate that mitochondria are the main intracellular
orchestrator of IP-induced cytoprotection, following the
opening of mitochondrial potassium channels (mitoKATP)
that trigger anti-apoptotic responses [60]. Mitochondria
primed by IP also contribute to cell survival by attenuating
proton leakage from the inner membrane [61].
Taking advantages from the knowledge of the molecu-
lar mechanisms leading to cell survival during organ IP,
in-vitro simulations of this strategy have been adopted
to improve resistance of cultured cells against harmfulTable 1 Effects of reduced oxygen tension on SC survival
Cell type pO2 modulation Increased cell surviv
Mouse peripheral blood
mononuclear cells
Continuous hypoxia Increased oxidative st
Rat MSCs Continuous hypoxia Reduced apoptosis/ac
ERK, NADPH oxidase
BM-MSCs Continuous hypoxia Akt activation and cM
Skeletal myoblasts Cyclic hypoxia Improved resistance t
Human MSCs Continuous hypoxia
BM-MSCs Anoxia Reduced apoptosis
Murine MSCs Continuous hypoxia Increased Wnt4 expre
Mouse BM-MSCs Continuous hypoxia HIF-1α-dependent CX
overexpression
MSCs CoCl2 HIF-1α-dependent CX
HUVECs Cyclic hypoxia Increased cicloxygena
MSCs Cyclic hypoxia HIF-1α dependent act









MSCs Cyclic hypoxia HIF-1α-dependent Ak
activation and PDC10
MSCs diazoxide NF-kB activation
Skeletal myoblasts (SMs) diazoxide Prevented apoptosis/a
HGF, cycloxigenase-2conditions of hypoxia. Therefore “Hypoxia Precondi-
tioning” (HP), which is characterized by intermittent
periods of hypoxia, or anoxia, followed by reoxygenation
[62-64], has been applied with different protocols to
improve survival of cultured SCs.
Continuous hypoxia, rather than cyclic hypoxia, was
also able to activate intracellular signal transduction
pathways of survival in adult SCs, together with other
processes useful for regenerative medicine, such as SC
proliferation and paracrine activity [65-67]. However, the
effectiveness of cycling/intermittent hypoxia/anoxia fol-
lowed by reoxygenation was demonstrated to be superior
than continuous hypoxia. Heider and Ashraf observed that
cycles of intermittent anoxia and reoxygenation better
preconditioned skeletal myoblasts than one-time continu-
ous exposure to anoxia of the same duration and intensity
[68]. Moreover, the leakage of lactate dehydrogenase
from myoblasts subjected to lethal anoxia treatmental/ mechanism Host tissue/effects Ref.
ress resistance Ischemic hind limb/increased
angiogenesis
[65]
tivation of Akt, [66]
ET upregulation Ischemic hind limb/increased
angiogenesis
[67]
o lethal anoxia [68]






ssion Ischemic hind limb/increased
angiogenesis and MSC retention,
proliferation, migration
[71]










Infarcted heart/higher MSC survival [76]








Infarcted heart/increased MSC survival [80]
[88]
ctivation of Akt, bFGF, Infarcted rat heart/higher SM survival
and increased cardiac contractility,
angiogenesis
[89]
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prime cells, as well as other indexes of cell damage,
including TUNEL positivity, hypercontracture and spher-
ical morphology of cells. Nevertheless, most protective
protocols have used a single long-term exposure to low
oxygen tensions, equal or lower than 5%; hence, hereafter
we will extend the term HP to non-lethal continuous
hypoxia.
MSCs preconditioned with HP not only survived better
to transplantation in a swine model of chronic myocardial
ischemia but also ameliorated cardiac function [69].
Improved anti-apoptotic and anti-remodeling potency
of bone marrow MSCs was also observed in a model of
diabetic cardiomyopathy [70]. HP was demonstrated to
be effective for the regeneration of other tissues besides
the infarcted myocardium, including skeletal muscle
fibers [71] and kidney [72]. Renal lesions due to acute
ischemia were also regenerated using MSCs pretreated
with cobalt chloride (CoCl2) which simulates HP, since
divalent cations such as the Co2+ compete with iron
and inhibit the activity of PHDs, leading to stabilization
of HIF-1α [73]. Under this condition the effectiveness
of cell therapy was enhanced by the activation of MSC
migration towards the injured region of the kidney.
Another evidence of the beneficial effects of HP in
increasing cell survival was demonstrated by Daneau
et al. [74] in human umbilical vein endothelial cells
(HUVECs) that were subjected to three periods of one
hour each at 0.5% O2 concentration, interrupted by
30 minutes of reoxygenation. These positive effects did
not occur when three hours of continuous hypoxia
were applied rather than the same time-period of inter-
mittent hypoxia.
HIF-1α-dependent signal transduction pathway in SCs
As mentioned above, the efficacy of HP is mainly as-
cribed to HIF-1α activity. HIF-1α-dependent Akt phos-
phorylation was responsible of the increased survival in
MSCs preconditioned with two cycles of 30 minutes of
anoxia/reoxygenation [68]. Moreover, a selected group
of miRs downstream to HIF-1α were found to protect
MSCs against hypoxia [75]. Kim et al. [76] demon-
strated that HP could increase the survival of MSCs by
upregulating miR-210 and its concentration correlated
to the number of anoxia/reoxygenation cycles. The
principal target gene of miR-210 that is responsible of
cytoprotection is FLASH/caspase-8-associated protein
2 (CAP8AP2), a molecule that significantly reduced
apoptosis in the MSCs treated with HP when subjected
to lethal anoxia. Accordingly, transgenic induction of
miR-210 in MSCs promoted their survival as well and
increased the resistance to death in MSC engrafted in the
infarcted heart [77]. Strikingly, when miR-210-transduced
MSCs were cultured with cardiomyocytes, some miRswere transferred to cardiac cells that acquired higher
protection. Functional links between HIF-1α and miR-
210 against apoptosis were also observed in hypoxic
endothelial cells [78] and cancer cells [79]. Besides miR-
210, HP was also able to induce miR-107 in MSCs as a
consequence of HIF-1α activation [80]. One major puta-
tive target of miR-107 was identified as the programmed
cell death-10 (PDC10) protein which is regulated by
HIF-1α independently from CASP82.
Other targets of HIF-1α have been discovered in MSCs
treated with HP, such as the SDF-1 receptors CXCR4
and CXCR7 [81,82]. Therefore, the effects of SDF-1 are
potentiated in MSCs after HP as demonstrated in the
ischemic and reperfused kidney [72]. The improvement
of HIF-1α-dependent survival of HUVECs exposed to HP
was correlated to an increased expression of cycloxy-
genase-2 [74]. Other mechanisms have been linked to the
protective effects of HP, including Wnt-4 [71] and Notch-
stimulated Jagged2 activation as observed in cultured
CSCs [83,84].
Diazoxide treatment simulating IP
Pharmacological manipulations simulating the effects of
HP in adult SCs would represent a more convenient
alternative to hypoxic treatments due to the ease of drug
administration. In this regard, MSCs were precondi-
tioned with diazoxide, a mitoKATP channel opener
extensively experienced as IP mimetic for cardiac protec-
tion [85,86]. The effectiveness of diazoxide in preventing
cardiomyocytes apoptosis was correlated to multiple
transduction signaling cascades involving a preliminary
translocation of both Akt and PKCδ into mitochondria
and the subsequent phosphorylation of mitoKATP
channels, leading eventually to the inhibition of cyto-
chrome c release into cytosol [87]. Other mechanisms
related to the diazoxide treatment have been described,
such as improved MSC survival through the activation
of nuclear factor kB (NF-kB) [88] and increased protection
and angiogenic properties in skeletal myoblasts via
release of cytokines and growth factors [89]. Among
them, VEGF exerts a dual role in promoting both tissue
neovascularization [90] and cell survival [91,92], as also
demonstrated in SCs [93,94]. Accordingly, VEGF can
facilitate the commitment of circulating mononuclear
cells towards the formation of EPCs [95,96] and their
recruitment in ischemic tissues [97]. In addition, VEGF
stimulates iPSCs to differentiate into cardiac muscle
cells [98].
Besides diazoxide, several chemical compounds have
also been demonstrated to be effective in preconditioning
SCs by improving their survival, proliferation, and differ-
entiation either in vitro or after transplantation in pre-
clinical models (Table 2) [99-108]. Since the mechanisms
of action of these drugs are different from those
Table 2 Chemicals and cytokines useful for
preconditioning SCs before their transplantation
SC type Chemical/cytokine
Neural SCs isoflurane [99], interleukin-6 [100]
EPCs sevoflurane [101]
MSCs oxytocin [102], angiopoietin-1 [103], hydrogen
peroxide [104], transforming growth factor-α
[105], , trimetazidine [106]
ADSCs sydenafil [107]
Cardiac SCs cobalt protoporphyrin [108]
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discussed further.
Effects of hypoxia pretreatments on SC differentiation
Hypoxic stimulation of neurogenesis
As described above, SC quiescence can be favored by
the hypoxic environment of the niche. By contrast, other
studies underline that hypoxia can be also responsible,
at least in part, of the following steps in the life of SCs,
namely proliferation and differentiation. Since quies-
cence, expansion, and differentiation are processes that
cannot temporarily co-exist in the same cell, it is not
clear how a condition of hypoxia can provoke such
different biological events. A possible explanation is
provided by the knowledge that hypoxia is not the only
featuring factor operating in the SC niche because also
different cell types and ECM/paracrine-related signals are
present in that microenvironment. Thus, only a tunable
orchestration of all components of the niche can allow
SCs to take one or another direction towards a specific
biological process. For example, studies focusing on adult
neurogenesis underlined the relevant role played by the
brain niche where neural stem cells (NSCs) reside and
generate new neurons [109,110]. In the healthy humanTable 3 Effects of reduced oxygen tension on SC differentiati
Cell type pO2 modulation
BM-MSCs CoCl2
Rat MSCs Continuous hypoxia
Human MSCs Continuous hypoxia
MSCs Continuous hypoxia
BM-MSCs Continuous hypoxia in alginate beads
Human BM-MSCs Continuous hypoxia in gelatine hydrogel
Human ADSCc Continuous hypoxia and chondrogenic medium
ADSCc Continuous 2% oxygen tensionadult brain, the subventricular zone (SVZ) and specific
areas of the hippocampus have been identified as regions
where thousands of new neurons can stem from NSCs
[111,112]. Since the physiological concentrations of oxy-
gen in the brain range from 0.5% (midbrain) to 8% (pia)
[113], it can be hypothesized that NSCs display intermedi-
ate levels of hypoxia during their migration from the niche
towards other regions and consequently modulate their
state of differentiation. Likewise, it has been suggested that
an ischemic event in the brain can stimulate neurogenesis
not only in the NSC niches but also in other injured areas
where NSCs are migrated.
The involvement of brain hypoxia in promoting NSC
proliferation and differentiation has encouraged the re-
searches to pilot the NSC behavior under culture condi-
tions of hypoxia. As extensively reviewed by Vieira et al.
[114], several ex-vivo approaches have demonstrated
that SC proliferation and differentiation into the neural
lineage are enhanced in the presence of 2% to 5% O2 or
using CoCl2 treatments. Besides adult NSCs and neural
precursor cells, cobalt increased also MSC commitment
towards dopaminergic neuron-like cells. Notably, the
process of differentiation was associated with an increased
expression of HIF-1α together with its target genes
erythropoietin, VEGF, and p21 [115] (Table 3).
The possible role of reactive oxygen species (ROS) in
these models of neurogenesis has been highlighted, since
oxidative stress can increase in SCs subjected to low
oxygen concentrations [29,116]. Interestingly, the contri-
bution of ROS was confirmed by studies in which neural
differentiation was obtained in the PC12 cell line sub-
jected to hyperoxia and prevented by antioxidant treat-
ments [117]. However, although HIF-1α itself and
several genes regulating cell redox response are known
to be targeted by ROS [118], the mechanistic link which
induces SCs to undergo differentiation remains to be
elucidated.on
Cell differentiation/ mechanism Ref.
Dopaminergic neuron-like cells/HIF-1α
dependent activation of EPO, VEGF, p21
[115]
Increased chondrogenesis/activation of HIF-1α,
Akt, p38 MAPK, SOX-9
[119]
Inhibited osteogenesis/ HIF-1α dependent
inhibition of RUNX2
[121]
Inhibited hypertrophic chondrogenesis [122]
Increased chondrogenesis/ HIF-1α




Decreased chondrogenesis and osteogenesis [127]
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Cartilage is another tissue which is widely investigated
for regenerative therapy and that is naturally subjected
to low oxygen tension since it is devoid of any vasculature.
Due to this particular characteristic, oxygen levels grad-
ually decrease from both superficial and calcified zone
to the inner zone of cartilage. There is a general agree-
ment in stating that hypoxia can stimulate MSCs to
differentiate into chondrocytes. Hypoxia enhanced chon-
dro-specific differentiation of the MSC line C3H10T1/2
increasing the biosynthesis of both collagen type II and
aggrecan by the p38 MAPK pathway [119]. Hypoxic
conditions increased SOX-9 expression in human MSCs
via HIF-1α but also HIF-2α seems to be involved, at
least in articular chondrocyte differentiation [120]. On
the contrary, hypoxia inhibits RUNX2 expression because
of the upregulation of HIF-1α and TWIST [121]. There-
fore, under hypoxic conditions MSCs are almost impeded
to differentiate into osteoblasts, an event that instead is
observed during the progression of osteoarthritis due to
the vascularization of cartilage. Likewise, hypoxia inhibits
collagen type X production counteracting hypertrophic
chondrogenesis [122].
In view of regenerative medicine applications, Duval
et al. [123] grew bone marrow MSCs (BM-MSCs) in al-
ginate beads under hypoxic conditions without addition
of exogenous growth factors. BM-MSCs underwent chon-
drogenesis after seven days, as confirmed by HIF-1α
and SOX-9 overexpression. In another study similar
results were obtained using gelatin-based hydrogel as
substrate [124].
Stem cells with mesenchymal features like BM-MSCs
that can be isolated from the adipose tissue (ADSCs)
[125] showed also the potential to differentiate into
chondrocytes when subjected to hypoxia [126]. Strikingly,
O2 concentration as low as 2% decreased chondrogenesis
and osteogenesis in ADSCs exposed to the corresponding
differentiating media [127]. Therefore, oxygen tensions
ranging from 2% to 5% should be considered as the opti-
mal O2 concentrations for ADSC commitment towards
chondrogenesis.
Other putative mechanisms by which preconditioned SCs
can improve organ function
Besides the enhanced survival and differentiation of the
SCs themselves, it is possible that the hypoxic pretreat-
ments of SCs produce other beneficial effects in the
injured host tissue. It is known that several effects of SC
therapy are due to the paracrine activity of these cells.
Multipotent SCs synthesize a broad spectrum of soluble
mediators that include molecules with immunomodula-
tory, anti-apoptotic, pro-angiogenic, and chemoattractive
effects. For example, the transplantation of MSCs in
the infarcted heart has been described to improvecardiac contractility especially because of the sustained
release of growth factors from MSCs rather than their
transdifferentiation into cardiac muscle cells [128].
However, partial oxygen pressures can significantly
affect the profile of these paracrine mediators, and
therefore, change the biological response of the target
cells. In particular, several angiogenic growth factors
that are normally released by MSCs, including VEGF
and HGF, are produced to a greater extent if MSCs are
exposed to hypoxic conditions [129]. Anyway, at least
as a consequence of the enhanced viability of the
preconditioned SCs in the injured tissue, the amount of
released growth factors and their permanence during
the regenerative process should be increased as well.
Finally, it should be also taken into consideration that
several approaches of tissue engineering require 3D
scaffolds where oxygen diffusion to the embedded cells
can be made difficult due to the thickness and low
porosity of the supporting material [130]. Therefore, a
preventive adaptation of SCs to a condition of partial
hypoxia should improve the effectiveness of construct
transplantation.Conclusions
Making SC transplantation a really efficient procedure is
one of the major challenge for regenerative medicine.
Discovering simple and safe strategies for increasing
survival and favoring differentiation of grafted cells will
pave the way for new suitable interventions for tissue
repair. Treating SCs with HP have been demonstrated to
increase resistance against cell death and to promote
proliferation and differentiation towards specific cell
lineages. However, easier pharmacological cell handling
recapitulating decisive intracellular effects induced by
HP or IP could represent a forward tool to improve cell
therapy and encourage tissue engineering applications.
Different factors such as autacoids (e.g. adenosine,
bradykinin, opioids), cytokines (e.g. erythropoietin),
their receptors and signal transduction pathways, and
mitochondrial function are implicated in the protection
induced by IP [131]. Several molecular steps are ac-
tivated, including extracellular regulated kinase 1/2,
phosphatidylinositol 3 kinase/Akt, protein kinase C,
and protein kinase G, which are able to inhibit glyco-
gen synthase kinase-3β and, in turn, the opening of the
mitochondrial permeability transition pore [132]. Also
mitochondrial ROS are consistently involved in the
causative mechanisms of IP [133]. The protection induced
by IP is not more operating after a few hours after the last
cycle of ischemia/reperfusion but reappears 24 hours later.
This “delayed” IP is due to the synthesis of protective pro-
teins, including heat shock proteins, manganese super-
oxide dismutase, and inducible nitric oxide synthase [134].
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of drugs affecting these pathways could be investigated
as IP mimetics to exert protection. For example, clinical
trials have demonstrated that adenosine or erythropoi-
etin administration are effective in cardioprotection by
significantly reducing the infarct size [135,136]. There-
fore, besides diazoxide, other drugs simulating hypoxic
treatments should be investigated to provide protection
to SCs before their transplantation.
Although low oxygen tension-based pretreatments
have demonstrated to give considerable results on SC
viability and functional performance, the in-vivo short-
term permanence of these beneficial effects still repre-
sents a problem to be solved. In order to obtain a more
stable action of SCs in the damaged tissues, gene therapy
inducing the SC expression of adaptive molecules to the
ischemic environment could likely represent a future
approach. Alternatively, biomaterials releasing HP/IP mi-
metics and contemporary conveying SCs [137] could
also prolong cell activity after grafting and improve the
overall process of tissue regeneration. In addition, bioreac-
tors for high-throughput cell yield providing hypoxic
cell cultures chambers should be employed to give a
sufficient amount of preconditioned SCs to regenerate
the injured region [138,139]. Future interdisciplinary
studies investigating these issues will surely contribute to
upgrade these basic researches for clinical applications.
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